SLEEP 2013 Keynote Addresses

I01: Evolution of Insomnia: Patient to Population, Primary to Comorbid, Laboratory to Clinic and Pathophysiology to Therapeutics

1. Discuss changes in the understanding of insomnia as a condition over the past 50 years;
2. Identify the prevalence and risk factors for developing insomnia; and
3. Appreciate the views of the pathophysiology of insomnia and its implications for therapy.

Thomas Roth, PhD Thomas Roth, PhD, is the Director of the Sleep Disorders and Research Center at Henry Ford Hospital in Detroit, a Professor in the Department of Psychiatry at Wayne State University, School of Medicine in Detroit, Michigan, and a Clinical Professor in the Department of Psychiatry at the University of Michigan, College of Medicine in Ann Arbor. After serving as president of the Sleep Research Society and the founding president of the National Sleep Foundation (NSF), Dr. Roth became chairman of the National Center on Sleep Disorders Research advisory board. In addition, he was a member of the board of directors of the Associated Professional Sleep Societies, LLC (APSS), chaired the APSS Program Committee and the governing board of the World Sleep Federation. Dr. Roth was instrumental in the formation of the Association of Sleep Disorders Centers (ASDC), now the AASM, and served as the organization’s second president. He is also the former Chairman of the World Health Organization’s worldwide project on sleep and health

In addition to authoring and numerous articles, Dr. Roth is a past editor-in-chief of the journal SLEEP and currently sits on the editorial boards of Sleep Reviews, Stress Medicine, and Advances in Therapy and Human Psychopharmacology. In 2002, Dr. Roth received the NSF’s Lifetime Achievement Award. He received a Distinguished Research Award from the Sleep Research Society as well as the Nathaniel Kleitman Award from the American Academy of Sleep Medicine. Dr. Roth received his doctorate from the University of Cincinnati and has since studied sleep homeostatic processes, sleep loss, sleep fragmentation, sleep pathologies and the effects of pharmacologic agents on sleep/wake function.

I02: NIH and Advances in Sleep Research: Past, Present and Future Opportunities

1. Discuss the role that the NIH has had in advancing sleep research; and
2. Review future opportunities for advancing sleep research.

Gary H. Gibbons, MD Gary H. Gibbons, MD, is Director of the National Heart, Lung, and Blood Institute (NHLBI) at the National Institutes of Health (NIH). The NHLBI provides global leadership for research, training, and education programs to promote the prevention and treatment of heart, lung, and blood diseases and enhance the health of all individuals so that they can live longer and more fulfilling lives. Prior to being named director of the NHLBI, Dr. Gibbons served as a member of the National Heart, Lung, and Blood Advisory Council (NHLBAC) from 2009-2012. Before joining the NHLBI, Dr. Gibbons served as the founding director of the Cardiovascular Research Institute, chairperson of the Department of Physiology, and professor of physiology and medicine at the Morehouse School of Medicine, in Atlanta.

Under his leadership of the Cardiovascular Research Institute, he directed NIH-funded research in the fields of vascular biology, genomic medicine, and the pathogenesis of vascular diseases. During his tenure, the Cardiovascular Research Institute emerged as a center of excellence, leading the way in discoveries related to the cardiovascular health of minority populations. Dr. Gibbons received several patents for innovations derived from his research in the fields of vascular biology and the pathogenesis of vascular diseases.